MedTrace Logo

Pharmacogenetic of Doxorubicin in HCC.

NCT06313047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2024-03-28

No results posted yet for this study

Summary

The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.

Conditions

Interventions

DRUG

Doxorubicin

each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.

Sponsors & Collaborators

  • King Saud Bin Abdulaziz University for Health Sciences

    collaborator OTHER

  • King Abdulaziz University

    collaborator OTHER

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Sireen Shilbayeh, Prof. · Princess Nourah Bint Abdul Rahman University

  • Mohammad A. Alshabeeb · King Saud Bin Abdulaziz University for Health Sciences

  • Abdalrhman H Alanizi · King Abdulaziz University

  • Naglaa Khedr, Prof. · Tanta University

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-15
Completion
2023-12-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06313047 on ClinicalTrials.gov